(Q72996749)

English

Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C

scientific article published on 01 October 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11003631%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11003631%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

amantadine sulfate

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

S Zeuzem

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11003631%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

G Teuber

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11003631%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

U Naumann

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11003631%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

T Berg

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11003631%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

J Raedle

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11003631%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

S Hartmann

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11003631%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

U Hopf

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11003631%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

language of work or name

0 references

publication date

1 October 2000

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11003631%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11003631%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

32

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11003631%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

4 Pt 1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11003631%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

835-841

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11003631%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Therapy of hepatitis C: overview

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical evaluation of a new polymerase chain reaction assay (Amplicor HCV) for detection of hepatitis C virus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influenza virus. Amantadine blocks the channel

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of dengue virus replication by amantadine hydrochloride

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The molecular basis of the specific anti-influenza action of amantadine

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of chronic hepatitis C with amantadine

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis C virus six years on.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro inhibition of rubella virus by 1-adamantanamine hydrochloride

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Classification of chronic hepatitis: diagnosis, grading and staging

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of amantadine on mouse hepatitis virus replication

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of uncoating of fowl plague virus by l-adamantanamine hydrochloride

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Arenaviruses: inhibition by amantadine hydrochloride.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11003631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1053/JHEP.2000.17740

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11003631%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11003631%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q72996749&oldid=1749867044"